Cellect Biotechnology Ltd. (APOP) secured a European patent covering a method of treatment from the European Patent Office. The patent covers cell-based therapeutics of Cellect’s technology and method that have the potential to treat diseases like diabetes, graft-versus-host disease, inflammatory bowel disease, and transplant rejection.
The patent is related to the technology of regulatory immune cells with enhanced apoptotic activity, which is a process of programmed cell deaths that occur in organisms. The apoptotic activity is used for immuno-modulation, which is a process of modification of the immune response or the functioning of the immune system by the action of an immuno-modulator, and is used for the treatment or prevention of immune-related disorders.
Patent Protection to Bolster Future Pipeline
While Cellect’s current drug pipeline does not include the therapeutics covered in the patent, it offers promising potential for enhancing the company’s future pipeline. Earlier this year, Cellect received a Notice of Allowance from the U.S. Patent & Trademark Office for the same patent.
“Now covering both the U.S. and the EU, this patent is a base for the future commercialization of our global business. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine," said Cellect CEO Shai Yarkoni. "With this patent, Cellect has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments."
In March 2017, the Tel Aviv, Israel-based company announced success in performing the first stem cell transplant procedure using its ApoGraft technology in a Phase 1/2 clinical trial in a blood cancer patient. (For more, see Cellect Succeeds In First Stem Cell Transplant.)
Following the update, Cellect's stock price jumped 23% to $10.64 per share on Monday morning.